Inicio/Acciones/MAIA

MAIA

USD

MAIA Biotechnology Inc. Common Stock

$1.130-0.030 (-2.586%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$1.160

Máximo

$1.160

Mínimo

$1.125

Volumen

0.12M

Fundamentos de la Empresa

Capitalización de Mercado

37.3M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.58M

Bolsa

ASE

Moneda

USD

Rango de 52 Semanas

Mínimo $1.12Actual $1.130Máximo $3.48

Noticias Relacionadas

27 oct 2025 · 14:45

GlobeNewswire

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

23 oct 2025 · 12:36

GlobeNewswire

MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage

MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

13 oct 2025 · 20:20

GlobeNewswire

MAIA Biotechnology Announces $736,600 Private Placement

CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced

MAIA Biotechnology Announces $736,600 Private Placement

7 oct 2025 · 13:00

PR Newswire

Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

USA News Group News Commentary – Major pharmaceutical companies are unveiling breakthrough cancer data at the European Society for Medical Oncology...

Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

7 oct 2025 · 12:47

GlobeNewswire

MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets

MAIA's Board of Directors authorizes holdings of up to 90% of the Company's liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology,